SRZNW
Surrozen, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
−60.53%Margins
Gross margin
99.4%
EBITDA margin
-2883.4%
EBIT margin
-385.3%
Net margin
-2885.3%
FCF margin
-303.9%
151.9%
Return on equity
-287.3%
Return on assets
20.9%
Return on invested capital
0.10x
Asset turnover
-$34.8M
Cash from operations
$12
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026